Petra Hillmann

1.8k total citations · 1 hit paper
28 papers, 1.3k citations indexed

About

Petra Hillmann is a scholar working on Molecular Biology, Organic Chemistry and Pathology and Forensic Medicine. According to data from OpenAlex, Petra Hillmann has authored 28 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 7 papers in Organic Chemistry and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Petra Hillmann's work include PI3K/AKT/mTOR signaling in cancer (16 papers), Tuberous Sclerosis Complex Research (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Petra Hillmann is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (16 papers), Tuberous Sclerosis Complex Research (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Petra Hillmann collaborates with scholars based in Switzerland, Germany and United States. Petra Hillmann's co-authors include Doriano Fabbro, Barbara Chaneton, Agnés C. L. Martin, Karen H. Vousden, Finn P. Holding, Achuthanunni Chokkathukalam, Christian Frezza, Eyal Gottlieb, Marc O’Reilly and Joseph E. Coyle and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Petra Hillmann

27 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Serine is a natural ligand and allosteric activator of pyruvate kinase M2

2012 497 citations Barbara Chaneton, Petra Hillmann et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Petra Hillmann Switzerland	15	963	346	183	131	124	28	1.3k
Roland Neuhaus Germany	16	732 0.8×	265 0.8×	123 0.7×	191 1.5×	50 0.4×	35	1.1k
Lourdes Toral‐Barza United States	28	1.9k 2.0×	301 0.9×	514 2.8×	301 2.3×	87 0.7×	41	2.6k
Geoffrey Lawton United Kingdom	13	904 0.9×	165 0.5×	275 1.5×	166 1.3×	51 0.4×	20	1.4k
Peter D. Davis United Kingdom	19	1.2k 1.2×	244 0.7×	554 3.0×	299 2.3×	58 0.5×	39	2.0k
Justine Rudner Germany	21	895 0.9×	229 0.7×	44 0.2×	266 2.0×	52 0.4×	30	1.2k
Christopher H. Hill United Kingdom	14	960 1.0×	122 0.4×	353 1.9×	152 1.2×	54 0.4×	22	1.5k
Mandi M. Murph United States	23	1.6k 1.7×	281 0.8×	38 0.2×	214 1.6×	97 0.8×	44	1.9k
Shuangxing Yu United States	27	2.7k 2.8×	560 1.6×	86 0.5×	436 3.3×	100 0.8×	33	3.2k
Lucie Brisson France	21	1.0k 1.1×	632 1.8×	35 0.2×	189 1.4×	118 1.0×	39	1.6k
Julie Laferrière Canada	9	744 0.8×	323 0.9×	150 0.8×	186 1.4×	27 0.2×	9	995

Countries citing papers authored by Petra Hillmann

Since Specialization

Citations

This map shows the geographic impact of Petra Hillmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petra Hillmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petra Hillmann more than expected).

Fields of papers citing papers by Petra Hillmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petra Hillmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petra Hillmann. The network helps show where Petra Hillmann may publish in the future.

Co-authorship network of co-authors of Petra Hillmann

This figure shows the co-authorship network connecting the top 25 collaborators of Petra Hillmann. A scholar is included among the top collaborators of Petra Hillmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petra Hillmann. Petra Hillmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jóźwiak, Katarzyna, Mieke Raap, Stephan Bartels, et al.. (2025). Clinicopathological Characteristics of a Distinct Tumor Phenotype: Invasive Lobular Carcinoma With Tubular Elements in the West German Study Group ADAPTcycle Trial. Laboratory Investigation. 105(6). 104125–104125. 2 indexed citations

Antony, Justin S., Petra Hillmann, Hervé Schaffhauser, et al.. (2023). Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative therapeutic potential in vivo. Molecular Therapy — Nucleic Acids. 34. 102055–102055. 4 indexed citations

Borsari, Chiara, Erhan Keleş, Denise Rageot, et al.. (2020). 4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. Journal of Medicinal Chemistry. 63(22). 13595–13617. 18 indexed citations

Theilmann, Wiebke, Birthe Gericke, Syed Muhammad Muneeb Anjum, et al.. (2020). Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology. 180. 108297–108297. 23 indexed citations

Borsari, Chiara, Denise Rageot, Thomas Bohnacker, et al.. (2019). A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. Journal of Medicinal Chemistry. 62(18). 8609–8630. 30 indexed citations

Gericke, Birthe, Claudia Brandt, Wiebke Theilmann, et al.. (2019). Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model. Neuropharmacology. 162. 107817–107817. 17 indexed citations

Fabbro, Doriano, Denise Rageot, Florent Beaufils, et al.. (2019). Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD. Neuropharmacology. 162. 107812–107812. 14 indexed citations

Tarantelli, Chiara, Eugenio Gaudio, Petra Hillmann, et al.. (2019). The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers. 11(6). 775–775. 12 indexed citations

Rageot, Denise, Thomas Bohnacker, Erhan Keleş, et al.. (2019). (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. Journal of Medicinal Chemistry. 62(13). 6241–6261. 49 indexed citations

10.

Hillmann, Petra & Doriano Fabbro. (2019). PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases. International Journal of Molecular Sciences. 20(22). 5792–5792. 67 indexed citations

11.

Brandt, Claudia, Petra Hillmann, Andreas Noack, et al.. (2018). The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. Neuropharmacology. 140. 107–120. 63 indexed citations

12.

Beaufils, Florent, Vladimir Cmiljanović, Thomas Bohnacker, et al.. (2017). 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Journal of Medicinal Chemistry. 60(17). 7524–7538. 115 indexed citations

13.

Gaudio, Eugenio, Petra Hillmann, Filippo Spriano, et al.. (2016). The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas. European Journal of Cancer. 69. S38–S38. 1 indexed citations

14.

Tarantelli, Chiara, Eugenio Gaudio, Ivo Kwee, et al.. (2015). The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas. Blood. 126(23). 4005–4005. 1 indexed citations

15.

Tarantelli, Chiara, Eugenio Gaudio, Ivo Kwee, et al.. (2014). The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response. Blood. 124(21). 1782–1782. 1 indexed citations

16.

Chaneton, Barbara, Petra Hillmann, Liang Zheng, et al.. (2012). Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 491(7424). 458–462. 497 indexed citations breakdown →

17.

Hillmann, Petra, et al.. (2009). Key Determinants of Nucleotide-Activated G Protein-Coupled P2Y₂ Receptor Function Revealed by Chemical and Pharmacological Experiments, Mutagenesis and Homology Modeling. Journal of Medicinal Chemistry. 52(9). 2762–2775. 72 indexed citations

18.

Baqi, Younis, et al.. (2008). ChemInform Abstract: Combinatorial Synthesis of Anilinoanthraquinone Derivatives and Evaluation as Non‐Nucleotide‐Derived P2Y₂ Receptor Antagonists.. ChemInform. 39(25). 11 indexed citations

19.

Hillmann, Petra, et al.. (2007). Ammonium-induced calcium mobilization in 1321N1 astrocytoma cells. Toxicology and Applied Pharmacology. 227(1). 36–47. 13 indexed citations

20.

Baqi, Younis, et al.. (2007). Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 18(1). 223–227. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact